AstraZeneca/Avillion Asthma Combo Draws Split Decision At FDA Panel; Data Was ‘All Over The Place’

 
• By Sue Sutter
  
Beads
Several panelists on both sides of the vote in adolescents said they would give deference to FDA on this population in light of the agency’s past experience with extrapolating adult efficacy data. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers